ViaCyte is one of the most exciting stem cell and regenerative medicine biotech companies so I like to try to check in with them regularly. Today’s post is my new interview with ViaCyte leader Paul Laikind on recent developments. We had a great chat about the science and how things are looking upbeat for the […]
ViaCyte Q&A: CRISPR Tx quick progress, ongoing diabetes trial, & more Read More »
UK biologist Kathy Niakan has asked governmental permission to make GM human embryos using CRISPR. Earlier this year, a research team in China crossed a scientific line for the first time in history by using gene editing technology called CRISPR-Cas9 to make genetically modified (GM) human embryos. Other researchers around the world including now one
UK Biologist Kathy Niakan Asks to Make GM Human Embryos For Research Read More »
The challenge to the WARF/Jamie Thomson patents/IP on human embryonic stem cells (hESC) is at an end. The US Supreme Court declined to hear the case. Earlier, the USPTO had turned down the challenge leading to a winding road in the courts. What do you all think of this stem cell IP challenge and the
Supreme Court Rejection of WARF hESC Patent Challenge Discussion Read More »
Federal funding of human embryonic stem cell (hESC) research is hanging by a tenuous thread at the moment. While currently legal, such funding is at the mercy of a legal case making its way through the courts. The latest stop for this case is a review by a 3-judge panel of the DC Circuit Court.
Update on embryonic stem cell court case Read More »
Sometimes a top scientist makes news with a quote on research and that happened with Ian Wilmut recently on stem cells. Move away from research on human ES cells (hESC) in favor of very new and still largely unclear trans-differentiation technology? I say, no way. But, Bradley Fikes of the North County Times has reported
Ian Wilmut, Dolly’s dad, says dump hESC? What does this mean? Read More »
CIRM announced two sets of awards today that both should make major impact including its first clinical trial via Geron and $38 million for 27 basic biology studies. First Clinical Trial. Today CIRM awarded $25 million to support Geron’s FDA-approved clinical trial for spinal cord injury. This is CIRM’s first award to a for-profit company
CIRM funds $25 million for Geron trial, $38 million for basic biology Read More »